# VERZENIO (abemaciclib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/abemaciclib

> The FDA approved VERZENIO (abemaciclib), sponsored by ELI LILLY & Co (LLY), on February 26, 2018.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VERZENIO (abemaciclib) |
| Codes | LY2835219 |
| Sponsor | ELI LILLY & Co (LLY) https://sec-api.dev/companies/lly/catalysts |
| Indications | [Breast Neoplasms](https://sec-api.dev/indications/breast-neoplasms), [Glioma](https://sec-api.dev/indications/glioma) |
| Modality | small_molecule |
| FDA designations | priority review |

## Timeline

### September 28, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208716 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170928, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22

### February 26, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208855 ORIG-1 (Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval): submission_status AP, submission_status_date 20180226, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208855%22

### March 30, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208716 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20200330, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22

### October 12, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208716 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20211012, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22
- openFDA Drugs@FDA: "NDA208716 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20211012, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22
- openFDA Drugs@FDA: "NDA208716 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20211012, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22

### March 3, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208716 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20230303, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22
- openFDA Drugs@FDA: "NDA208716 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20230303, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22

### November 12, 2024: trial start

- Status: completed. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124655): "Initiation of Combination Trial with Quantum Leap Healthcare Collaborative: Atossa, in collaboration with Quantum Leap Healthcare Collaborative, announced that the first patient was dosed in their clinical trial evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®) as a neoadjuvant treatment for high-risk women with newly diagnosed ER+/HER2- breast cancer." https://www.sec.gov/Archives/edgar/data/1488039/000095017024124655/atos-ex99_1.htm

### November 13, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208716 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20241113, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22

### November 17, 2025: NDA/BLA submission

- Status: scheduled. Date confidence: exact.
- First seen 2025-11-12, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276140): "The Company expects to meet with the FDA on November 17, 2025, to discuss a development plan intended to support filing an NDA, including the potential use of expedited programs where eligible." https://www.sec.gov/Archives/edgar/data/1488039/000119312525276140/atos-ex99_1.htm

### 2026: topline data readout

- Status: scheduled. Date confidence: year.
- First seen 2025-11-12, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-276140): "Patient enrollment is expected to follow the planned Investigational New Drug (IND) filing in Q4 2025, with topline data anticipated in 2026." https://www.sec.gov/Archives/edgar/data/1488039/000119312525276140/atos-ex99_1.htm

### July 13, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208716 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20260713, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22

### September 18, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208716 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20260918, review_priority STANDARD; sponsor_name ELI LILLY AND CO; product VERZENIO (ABEMACICLIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208716%22

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Glioma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06413706 (A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06413706

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Glioma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06413706 (A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT06413706

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Breast Neoplasms.
- First seen 2026-11-13T22:20:01.181Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07935317 (A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07935317

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Breast Neoplasms.
- First seen 2026-11-13T22:20:01.181Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07935317 (A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07935317

### May 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Breast Neoplasms; Neoplasm Metastasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07174336 (A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07174336

### May to Aug 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Breast Neoplasms; Neoplasm Metastasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07174336 (A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." https://clinicaltrials.gov/study/NCT07174336

## Same indication

- [Piqray (alpelisib)](https://sec-api.dev/pdufa/alpelisib) (NVS)
- [Inluriyo™ (imlunestrant)](https://sec-api.dev/pdufa/imlunestrant) (LLY)
- [Iza-bren](https://sec-api.dev/pdufa/iza-bren) (BMY)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Safusidenib](https://sec-api.dev/pdufa/safusidenib) (NUVB)
- [Tukysa (tucatinib)](https://sec-api.dev/pdufa/tucatinib) (PFE)
- [(z)-endoxifen](https://sec-api.dev/pdufa/z-endoxifen) (ATOS)

Calendar months: [November 2025](https://sec-api.dev/fda-calendar/2025-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/abemaciclib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VERZENIO (abemaciclib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/abemaciclib

```bibtex
@misc{secapidev_pdufa_abemaciclib_20261116,
  title        = {VERZENIO (abemaciclib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/abemaciclib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_abemaciclib_20261116","title":"VERZENIO (abemaciclib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/abemaciclib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
